导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.21% | 2103/4773 |
| 近一周 | -1.51% | 2248/5465 |
| 近一月 | -2.94% | 2029/5421 |
| 近一季 | -0.90% | 1149/5231 |
| 近半年 | 0.80% | 1254/4920 |
| 近一年 | 4.94% | 1778/4394 |
| 近两年 | 49.91% | 1503/2954 |
| 近三年 | 32.90% | 975/2253 |
| 成立以来 | 95.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.14% 3541/4961 |
8.43% 2595/5312 |
- - |
- - |
| 2025 | 18.90% 2273/4813 |
-0.43% 2247/3635 |
3.20% 1111/4076 |
14.67% 2884/4524 |
0.91% 1668/4813 |
| 2024 | 19.03% 562/3463 |
4.69% 441/2808 |
-2.26% 1163/3014 |
16.45% 1451/3129 |
-0.11% 1323/3463 |
| 2023 | -8.39% 1010/2656 |
4.77% 875/2280 |
-4.35% 1145/2385 |
-1.80% 583/2515 |
-6.91% 1974/2655 |
| 2022 | -19.59% 871/2207 |
-12.76% 657/1919 |
6.97% 565/2016 |
-14.33% 1069/2113 |
0.57% 1483/2208 |
| 2021 | -1.40% 796/1822 |
-1.50% 504/1255 |
6.09% 768/1330 |
-6.05% 896/1466 |
0.44% 1112/1822 |
| 2020 | 41.55% 287/1250 |
-7.44% 544/1028 |
16.99% 401/1067 |
14.72% 263/1164 |
13.95% 320/1184 |
| 2019 | 42.97% 198/1092 |
25.49% 465/739 |
0.94% 142/788 |
4.61% 190/850 |
7.89% 383/918 |
| 2018 | -21.84% 223/834 |
- - |
-8.81% 248/631 |
-0.65% 193/660 |
-12.29% 433/682 |
| 2017 | 24.70% 119/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.13% 156/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 创金合信沪深300指数增强C VS. 长安沪深300非周期A(740101) |